APA (7th ed.) Citation

JAJ, M., J, M., NK, J., MDM, R., L, M., & D, P. (2026). Safety of intramuscular tixagevimab-cilgavimab (Evusheld®) administration in patients at risk of iatrogenic haematoma due to haematological disorders. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 32(1), 32. https://doi.org/10.1177/10781552241284944

Chicago Style (17th ed.) Citation

JAJ, Malherbe, Misko J, Jayawardena NK, Rawlins MDM, Manning L, and Purtill D. "Safety of Intramuscular Tixagevimab-cilgavimab (Evusheld®) Administration in Patients at Risk of Iatrogenic Haematoma Due to Haematological Disorders." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 32, no. 1 (2026): 32. https://doi.org/10.1177/10781552241284944.

MLA (9th ed.) Citation

JAJ, Malherbe, et al. "Safety of Intramuscular Tixagevimab-cilgavimab (Evusheld®) Administration in Patients at Risk of Iatrogenic Haematoma Due to Haematological Disorders." Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, vol. 32, no. 1, 2026, p. 32, https://doi.org/10.1177/10781552241284944.